These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 31030540

  • 1. The Real-Life Effectiveness and Safety of Omalizumab Updosing in Patients With Chronic Spontaneous Urticaria.
    Salman A, Comert E.
    J Cutan Med Surg; 2019; 23(5):496-500. PubMed ID: 31030540
    [Abstract] [Full Text] [Related]

  • 2. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data.
    Salman A, Demir G, Bekiroglu N.
    Dermatol Ther; 2019 Jul; 32(4):e12975. PubMed ID: 31145524
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Inflammatory cytokine levels and changes during omalizumab treatment in chronic spontaneous urticaria.
    Hoşgören-Tekin S, Eyüboğlu İP, Akkiprik M, Giménez-Arnau AM, Salman A.
    Arch Dermatol Res; 2024 May 25; 316(6):261. PubMed ID: 38795119
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
    Metz M, Staubach P, Bauer A, Brehler R, Gericke J, Kangas M, Ashton-Chess J, Jarvis P, Georgiou P, Canvin J, Hillenbrand R, Erpenbeck VJ, Maurer M.
    Theranostics; 2017 May 25; 7(5):1266-1276. PubMed ID: 28435464
    [Abstract] [Full Text] [Related]

  • 8. A patient-oriented approach to long-term use of omalizumab in chronic spontaneous urticaria.
    Ornek S, Kocaturk E.
    Cutan Ocul Toxicol; 2021 Dec 25; 40(4):305-311. PubMed ID: 34212792
    [Abstract] [Full Text] [Related]

  • 9. Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation.
    Brás R, Costa C, Limão R, Caldeira LE, Paulino M, Pedro E.
    J Allergy Clin Immunol Pract; 2023 Aug 25; 11(8):2392-2402. PubMed ID: 36720390
    [Abstract] [Full Text] [Related]

  • 10. Characterization of omalizumab updosing patterns and predictive factors in chronic spontaneous urticaria: A prospective multicentric observational study.
    Pierrard G, Bernier C, Du-Thanh A, Bara C, Soria A, Castelain F, Boccon-Gibod I, Hacard F, Delaunay J, de Montjoye L, Staumont-Salle D, Dezoteux F.
    Allergy; 2024 Sep 25; 79(9):2448-2457. PubMed ID: 39056480
    [Abstract] [Full Text] [Related]

  • 11. Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria.
    Zubiaga-Fernandez L, Testera-Montes A, Rondon C, Perez-Sanchez N, Gomez-Perez F, Vega-Chicote JM, Bartra J, Ferrer M, Eguiluz-Gracia I, Torres MJ.
    Clin Exp Allergy; 2024 Jun 25; 54(6):402-411. PubMed ID: 38343206
    [Abstract] [Full Text] [Related]

  • 12. The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria-CURE Results.
    Kolkhir P, Laires PA, Salameh P, Asero R, Bizjak M, Košnik M, Dissemond J, van Doorn M, Hawro T, Kasperska-Zajac A, Zajac M, Kocatürk E, Peter J, Parisi CAS, Ritchie CA, Kulthanan K, Tuchinda P, Fomina D, Kovalkova E, Khoshkhui M, Kouzegaran S, Papapostolou N, Du-Thanh A, Kamegashira A, Meshkova R, Vitchuk A, Bauer A, Grattan C, Staubach P, Bouillet L, Giménez-Arnau AM, Maurer M, Weller K.
    J Allergy Clin Immunol Pract; 2023 Feb 25; 11(2):610-620.e5. PubMed ID: 36481420
    [Abstract] [Full Text] [Related]

  • 13. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
    Acar A, Gerceker Turk B, Ertam Sagduyu I, Ceylan C, Ozturk G, Unal I.
    Cutan Ocul Toxicol; 2020 Sep 25; 39(3):249-253. PubMed ID: 32597235
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Jia HX, He YL.
    Am J Ther; 2020 Sep 25; 27(5):e455-e467. PubMed ID: 32427616
    [Abstract] [Full Text] [Related]

  • 16. Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: A post-marketing surveillance study.
    Hide M, Fukunaga A, Suzuki T, Nakamura N, Kimura M, Sasajima T, Kiriyama J, Igarashi A.
    Allergol Int; 2023 Apr 25; 72(2):286-296. PubMed ID: 36272899
    [Abstract] [Full Text] [Related]

  • 17. Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
    Costa C, Esteves Caldeira L, Paulino M, Santos DF, Silva SL.
    Int Arch Allergy Immunol; 2024 Apr 25; 185(3):260-266. PubMed ID: 38113870
    [Abstract] [Full Text] [Related]

  • 18. Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population.
    Kulthanan K, Tuchinda P, Chularojanamontri L, Likitwattananurak C, Ungaksornpairote C.
    J Dermatolog Treat; 2017 Mar 25; 28(2):160-165. PubMed ID: 27388043
    [Abstract] [Full Text] [Related]

  • 19. Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria.
    Yang, Yu R, Qian W, Zheng Q, Xiong J, Chen S, Chen A, Chen J, Fang S, Huang K, Cai T.
    Int Arch Allergy Immunol; 2023 Mar 25; 184(7):643-655. PubMed ID: 36996780
    [Abstract] [Full Text] [Related]

  • 20. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria.
    Foti C, Romita P, Ambrogio F, Fanelli M, Panebianco R, Vena GA, Cassano N, Ragusa M, Giuffrida R, Papaianni V, Borgia F, Cannavò SP, Guarneri F.
    Dermatol Ther; 2022 Feb 25; 35(2):e15248. PubMed ID: 34877757
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.